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Abstract To clarify the multiple functionality of connective
tissue growth factor (CTGF), we examined the effects of nascent
CTGF within the cell by transient expression. In Cos-7 cells,
expression of human CTGF induced an altered cell morphology.
It was associated with an increased cellular DNA content and
loose attachment, indicating the cells were in G2/M phase.
Overexpression of CTGF did not induce cell growth, whereas
recombinant CTGF efficiently stimulated the proliferation
extracellularly. These results indicate that intracellular CTGF
may act as an antimitotic agent, thus it should also be noted that
nascent CTGF was found to accumulate around the central
mitotic machinery.
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1. Introduction
Connective tissue growth factor (CTGF) was designated
based on the initial ¢nding that it had chemotactic and mito-
genic activity for ¢broblasts [1]. It is a cysteine-rich secretory
protein of 36^38 kDa, which is composed of 349 amino acid
residues [2,3], and belongs to the CCN family, which consists
of ctgf (human)/¢sp12 (mouse), cef10 (chick)/cyr61 (mouse),
nov (chicken) and several recently reported genes such as elm1/
wisp-1, ctgf-3/ctgf-L/wisp-2/cop1, and wisp-3 [2^5].
The biological function of CTGF has been found to be
diverse and complex. In addition to the fact that CTGF is
expressed during wound healing [6], which may be regarded as
the actual outcome in vivo of previously reported chemotactic
and mitogenic activities, novel integrated functional aspects of
CTGF were uncovered through our research on chondrocyte
growth and di¡erentiation. In seeking regulatory factors in-
volved in many stages in the process of endochondral ossi¢-
cation, we isolated a cDNA which is identical to that of
CTGF from a human chondrocytic cell line, HCS-2/8 [7^
10], and found it to be one of such cellular factors [11]. Since
this discovery, we have obtained evidence that CTGF plays a
central role in the growth and di¡erentiation of chondrocytes
[12]. Namely, di¡erential expression of CTGF mRNA was
observed to follow the course of chondrocyte di¡erentiation.
The highest level of CTGF expression was observed at the
hypertrophic stage, whereas relatively lower levels of expres-
sion were found in earlier stages [11,12]. Stimulation of pro-
liferation and di¡erentiation of chondrocytes is also con-
ducted by CTGF [12]. Furthermore, CTGF was found to be
involved in angiogenesis [14,15], which is required in the last
stage of endochondral ossi¢cation. Also of note, enhancement
of CTGF expression by bone morphogenetic protein 2, as well
as transforming growth factor-L was observed in HCS-2/8
cells [11]. As such, we are rediscovering CTGF as a potential
factor to promote endochondral ossi¢cation in many stages,
which may be called ‘ecogenin’.
The multiple function of CTGF is thought to comprise a
combination of several di¡erent functional properties. It is
known that secreted CTGF stimulates cell growth and other
e¡ects on chondrocytes through its speci¢c surface receptor(s)
[12,16]. Nevertheless, no investigation has been presented on
the intracellular e¡ect and behavior of CTGF in the express-
ing cells. Thus, in order to elucidate the complex functionality
of CTGF, we examined the putative intracellular functions of
CTGF before it is released from the cell via transient expres-
sion experiments. In the present study, a novel function of
CTGF through an alternative intracellular pathway is indi-
cated.
2. Materials and methods
2.1. Molecular clones
The human CTGF eukaryotic expression plasmid, pcDNA3.1(3)-
ctgf was described previously [16]. As a control, the parental plasmid,
pcDNA3.1(3) (Invitrogen, Groningen, The Netherlands) was pre-
pared as well. For the expression of a control protein, L-galactosidase,
another plasmid called pCH110 (Amersham Pharmacia Biotech, Upp-
sala, Sweden) was purchased and utilized. The plasmids were puri¢ed
through Qiagen Tip columns (Qiagen, Hilden, Germany) prior to
transfection experiments.
2.2. Cells
A monkey kidney cell line, Cos-7, was maintained in Dulbecco’s
modi¢ed Eagle’s medium (D-MEM) supplemented with 10% fetal
bovine serum (FBS) at 37‡C in humidi¢ed air containing 5% CO2.
2.3. DNA transfection
A cationic liposome-mediated DNA transfection technique was em-
ployed, using a commercially available reagent (LipofectAMINE:
Gibco BRL, Rockville, MD, USA). Cos-7 cells were seeded at a
density of 2U105 per 35 mm diameter tissue culture well 16 h prior
to transfection. DNA transfection was carried out following the man-
ufacturer’s optimized protocol for Cos-7 cells, using 1 Wg of plasmid
DNA per sample [17,18]. At 12 or 24 h post transfection, cells were
subjected either to metabolic labeling or to immuno£uorescence ex-
periments as described below.
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2.4. Metabolic labeling and radioimmunoprecipitation analysis
Twenty-four hours after transfection, cells were starved in D-MEM
without methionine containing 5% dialyzed FBS for 1 h at 37‡C.
Metabolic labeling was performed subsequently by adding 200 WCi
of L-[35S]methionine per sample for 2 h at 37‡C. After being labeled,
the cells were washed with D-MEM for the chase phase of the experi-
ments, and were maintained in 1 ml of growth medium. At 0 or 24 h
after chasing, cells were washed with Dulbecco’s phosphate-bu¡ered
saline (PBS) and harvested in 1 ml of a radioimmunoprecipitation
analysis (RIPA) bu¡er, as described previously [17,19]. The superna-
tant at the 24 h timepoint was also saved at 320‡C after adding
phenylmethylsulfonyl £uoride (PMSF) to a ¢nal concentration of
200 WM. Immunoprecipitation was carried out for both cleared cell
lysate and tissue culture supernatant with the anti-CTGF rabbit se-
rum [13] and protein G-Sepharose (Amersham Pharmacia Biotech).
After being washed six times with the RIPA bu¡er, a high-salt wash
bu¡er, and a low-salt wash bu¡er (twice each), as previously described
[19], the immunocomplex was dissociated in 1Usodium dodecyl sul-
fate (SDS) sample bu¡er containing 2.5% 2-mercaptoethanol, and
analyzed by SDS^polyacrylamide gel electrophoresis (PAGE). Prior
to autoradiography, signals were enhanced by £uorography, using a
commercially available reagent (Amplify: Amersham Pharmacia Bio-
tech).
2.5. Indirect immuno£uorescence analysis
Cells were seeded on a glass coverslip in a 35 mm diameter tissue
culture well. On those cells, DNA transfection was performed as de-
scribed above. Twelve or 24 h after transfection, cells were ¢xed in
3.5% formaldehyde in PBS, and were permeabilized in 0.1% NP40 in
PBS, as described previously [20]. Incubation with antibodies was
performed at 37‡C for 1 h, followed by an extensive wash with
PBS. The anti-CTGF rabbit serum and anti-K-tubulin mouse mono-
clonal antibody (Sigma, St. Louis, MO, USA) were used as primary
antibodies at a 200-fold dilution in 3% bovine serum albumin in PBS.
Fluorescein isothiocyanate-conjugated anti-rabbit goat IgG and tetra-
methylrhodamine isothiocyanate-conjugated anti-mouse goat IgG
(Sigma) were used at a dilution of U100 as secondary antibodies in
the same bu¡er. In the secondary antibody mixture, DAPI was also
added at a ¢nal concentration of 1 Wg/ml to visualize cellular DNA.
The mounted cells were viewed under an epi£uorescent microscope
(Olympus, Tokyo, Japan).
2.6. Cell growth assay
For the evaluation of the e¡ect of recombinant CTGF (rCTGF) on
Cos-7 cell proliferation, 10 000 cells were seeded in a well of a 24 well
tissue culture plate, in the presence or absence of 50 ng/ml of rCTGF
[16]. For the evaluation of the e¡ect of the intracellular expression of
CTGF on cell growth, 25 000 cells were seeded at the same scale
(24 well scale). DNA transfection for those cells was carried out
with 250 ng of plasmid DNA at a quarter scale of that described.
Cell counting was performed at 2 days post addition, or post trans-
fection.
3. Results
3.1. Expression of human CTGF in Cos-7 cells by DNA
transfection
Utilizing a eukaryotic expression plasmid of human CTGF,
in which a ctgf cDNA is driven by a cytomegalovirus pro-
moter, we could e⁄ciently express human CTGF in a monkey
kidney cell line, Cos-7. Expression of human CTGF was
¢rstly con¢rmed by metabolic labeling of the transfected cells
and subsequent RIPA (Fig. 1). Strong signals that were spe-
ci¢cally reactive to the anti-CTGF serum were detected im-
mediately after labeling with L-[35S]methionine. At this time
point, two distinct signals were present, which might represent
a pro-CTGF with unprocessed signal peptide as well as a
commonly recognized 36 kDa processed CTGF. Interestingly,
24 h after labeling, the band with slower migration in SDS^
PAGE almost completely disappeared, suggesting its identity
as a precursor. Of note, even after 24 h of chase, no CTGF or
its related protein was detectable in the culture supernatant of
the transfected cells (Fig. 1). Therefore, this system may be
useful for the analysis of early cellular events that are caused
by intracellular nascent CTGF before secretion. Immuno-
£uorescence analyses revealed that CTGF was found inside
the cells from 12 h post transfection with interesting intra-
cellular distribution patterns as described later (Fig. 2).
3.2. High levels of intracellular expression of CTGF give rise to
an altered cellular morphology in transfected cells
In CTGF-expressing cells, no evident alteration in morphol-
ogy was observed 12 h after transfection. Nevertheless, after
24 h, most CTGF-expressing cells displayed an abnormal
morphology. These cells were characterized by a loose attach-
ment to the tissue culture chamber surface with marked
changes in appearance (Fig. 2). The population with these
morphological phenotypes perfectly corresponded to CTGF-
positive immunostaining. CTGF-negative cells around the
CTGF-positive cells showed no such changes, which indicates
that these morphological changes are not transmissible, and
thus should not be the consequence of the extracellular CTGF
function.
3.3. The CTGF-induced altered morphology is associated with
increased cellular DNA content
The loosely attached CTGF-expressing Cos-7 cells re-
minded us of cells that are heading for mitosis. DAPI staining
showed that a major population of the CTGF-expressing cells
did actually contain increased amounts of nuclear DNA at the
time point of 24 h post transfection, which is precisely accom-
panied by the observed morphological changes (Fig. 3). Of
note, overexpression of an unrelated protein, bacterial L-ga-
lactosidase, yielded no such e¡ects, providing no link between
Fig. 1. Transient expression of human CTGF in Cos-7 cells. Cells
were transfected with either pcDNA3.1(3), or pcDNA3.1(3)-ctgf,
and metabolically labeled with L-[35S]methionine for 2 h. The label-
ing was followed by a chase period. Immunoprecipitation was per-
formed either with cell lysate or with tissue culture supernatant with
an anti-CTGF serum. Positions of molecular weight markers are
shown at the left of each panel in kilodaltons. Arrowheads indicate
speci¢c signals of human CTGF expression, whereas asterisks de-
note non-speci¢c signals with an apparent molecular weight of
10 kDa, which are also observed in negative controls.
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the overexpression process itself and the increase in DNA
content with morphological alteration. Interestingly, the typ-
ical alignment of mitotic chromosomes, which can be found in
the control cells, is apparently absent in the CTGF-expressing
cells. Thus, it can be concluded that the observed morpholog-
ical alteration and increased cellular DNA content were
caused by intracellular CTGF. Also, the increased DNA con-
tent without mitotic chromosomes indicates that those cells
should be in late G2 phase or at the G2/M boundary in the
cell cycle.
3.4. No mitogenic e¡ect of intracellular CTGF expression
An increased DNA content and loose attachment merely
indicate that cells are in the G2/M phase, whether intracellular
CTGF promotes the cells to enter, or arrests them in G2/M
phase. In addition, CTGF at a concentration under the detec-
tion threshold of RIPA might exert a receptor-mediated func-
tion. To address these concerns, we evaluated the mitogenic
e¡ects of transient CTGF expression. No positive e¡ects on
cell proliferation were observed even 48 h after transfection
(90.6% of the controls), while extracellular human recombi-
nant CTGF which was directly added to the tissue culture
medium e⁄ciently stimulated the proliferation of Cos-7 cells
within 48 h (153% of the controls). As such, the CTGF-ex-
pressing cells are likely to be arrested in, rather than rushed
to, G2/M phase, and producing no biologically signi¢cant ex-
tracellular CTGF within 48 h after transfection.
3.5. Intracellular distribution of nascent CTGF
As is seen in Fig. 2, transiently expressed CTGF was not
distributed evenly and di¡usely in the transfected cells at 12 h
post transfection. There seems to be a particular spot of ac-
cumulation for nascent CTGF. As such, we performed double
staining studies with antibodies against cellular proteins.
Among them, an antibody to visualize K-tubulin provided
distinctive ¢ndings (Fig. 4). In interphase cells, a single cen-
trosome is observed adjacent to the nucleus, which is accom-
panied by radial expansion of microtubule ¢bers. In this cell,
CTGF is found at the central portion of the radial expansion,
which involves the cell centrosome ^ a microtubule organiza-
tion center (MTOC). The observed localization of nascent
CTGF suggests a possible interaction of CTGF and the cen-
Fig. 2. Indirect immuno£uorescent detection of transiently expressed CTGF, which is accompanied by morphological alteration at 24 h post
transfection. Cells were transfected with pcDNA3.1(3)-ctgf and viewed at the indicated time points after transfection. The same ¢elds were
viewed by epi£uorescent (top) and phase contrast (bottom) microscopy. At 24 h post transfection, the CTGF-expressing cell population clearly
corresponds to the population with altered morphology, while no change is observed in the cells without CTGF expression. Photomicrographs
were taken at a magni¢cation of 165U.
Fig. 3. The loose-attaching morphology induced by CTGF is ac-
companied by increased cellular DNA content. Cos-7 cells were
transfected with either pcDNA3.1(3)-ctgf or pCH110 (a L-galactosi-
dase expression plasmid as a negative control), and stained with
speci¢c antibodies and DAPI. The same ¢elds were viewed under a
phase contrast (left) and epi£uorescent (middle and right) micro-
scope. Note that the DNA increase in naturally dividing cells is in-
dependent of L-galactosidase expression. Magni¢cation: 330U.
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tral mitotic machinery in exerting the observed e¡ect of intra-
cellular CTGF.
4. Discussion
As suggested by its name, CTGF is an intercellular media-
tor of mitogenic and chemotactic signals in ¢broblasts and
endothelial cells [1]. However, the fact that CTGF acts as a
multiple mediator of chondrocyte growth and di¡erentiation
prompted us to seek putative alternative pathways by which
di¡erent functions are mediated. Here, the present data indi-
cated such an alternative pathway in addition to its classical,
receptor-mediated functioning route. Surprisingly, while
working as a mitotic factor outside the cell, CTGF was found
to lead the cells to cell cycle arrest before being secreted. A
preliminary basis for the functional aspect of CTGF as a cell
cycle regulator was provided by its possible interaction with a
central part of the cell division apparatus. Additionally, this is
the ¢rst report describing a single protein with apparently
opposing extracellular and intracellular e¡ects on mitosis.
The intracellular function to a¡ect the cell cycle might pro-
vide new insights into how CTGF is able to accomplish such
complex missions as observed in wound healing and endo-
chondral ossi¢cation. CTGF exerts a variety of e¡ects to po-
tentiate either growth or di¡erentiation in chondrocytes. In
the course of di¡erentiation, gene expression of CTGF should
be duly regulated by cis- and trans-regulatory factors [21,22].
By such regulations, marked induction of CTGF gene expres-
sion is restricted to particular stages of cell di¡erentiation, as
is seen in the hypertrophic stage in chondrocytes, and in cer-
tain pathological conditions. Otherwise, the expression level
of CTGF is maintained at relatively low levels [6,12]. Not only
the gene regulation, but the secretion and activation mecha-
nisms of CTGF are di⁄cult to describe comprehensively. In
the present study, no detectable extra CTGF in the culture
supernatant (Fig. 1) and no mitogenic activity were observed
during the ¢rst 2 days of the posttransfection period. Several
ideas can account for the negative ¢ndings for active secre-
tion. One possibility is that Cos-7 cells might be defective for
CTGF processing and secretion. Another likely interpretation
is that it may take several days for CTGF to be secreted as a
soluble form in the medium. Indeed, a previous report has
shown that, in human foreskin ¢broblasts, most of the
CTGF remained cell-associated at least for 5 days [23].
Also, it is still possible that a processed form that cannot be
detected by our antibody may have been secreted, which is
however ignorable, since no CTGF activity was detected via
bioassay.
At present, it is not exactly clear at which point in the G2/
M phase the CTGF-expressing Cos-7 cells are arrested, or
how CTGF causes the cell cycle arrest. However, since most
of the a¡ected cells are characterized by loose attachment,
increased DNA content without chromosome alignment on
the metaphase plate, and no sign of nuclear division, it is
assumed that they are arrested at a certain stage between
late G2 and early M phases. In this context, the initial accu-
mulation of CTGF around the MTOC (Fig. 4) may be note-
worthy. If CTGF has direct interactions with microtubules, or
other centrosomal components, one possible mechanism for
the observed cell cycle arrest is that in those cells, the mitotic
process might be disrupted by spindle dysfunction, and they
may not pass the spindle damage/assembly checkpoint [24].
However, the possible interaction of CTGF and mitosis pro-
moting factor [25] and other factors to modify the phosphor-
ylation signaling for passing through mitotic checkpoints can-
not be disregarded [26,27]. The putative e¡ect of CTGF on
the recently reported p38 kinase function which is thought to
be involved in the spindle damage/assembly checkpoint must
be considered as well [28]. Analyses to clarify the intracellular
CTGF-mediated cell cycle arrest are currently ongoing, to-
gether with mutational analyses of CTGF to map the func-
tional domain which is responsible for this alternative func-
tion.
The antimitotic e¡ect of nascent CTGF seems to be contra-
dictory to the classical mitogenic e¡ect of CTGF. However, it
might still be a critical part of the CTGF functionality. As
generally recognized, cell di¡erentiation is usually accompa-
nied by restricted cell growth. Therefore, in certain di¡erenti-
ated cells, a very high level of CTGF expression could be an
intracellular signal of terminal di¡erentiation in the expressing
cells to halt their cell growth, while leading the secretion of
CTGF to stimulate the growth of other cell populations,
which is actually represented by the behavior of hypertrophic
chondrocytes in growth cartilage [11]. Namely, highest CTGF
expression is observed only in terminally di¡erentiated hyper-
trophic chondrocytes that present few CTGF-speci¢c receptor
molecules, whereas mature chondrocytes in the prehypertro-
phic stage display many functional receptors (Nishida et al.,
unpublished data). As such, the behavior of intracellular
CTGF and its relationship to the di¡erentiated phenotypes
in hypertrophic chondrocytes are to be dissected. In this re-
gard, it is also of note that apoptosis was induced by CTGF
expression in a particular breast cancer cell line [29]. We have
Fig. 4. Intracellular localization of nascent CTGF 12 h after trans-
fection. Enlarged images of a CTGF-expressing interphase cell to
examine the localization site of nascent CTGF. Indirect immuno-
£uorescence to visualize the distribution of K-tubulin was added.
The distinctive shape of the nucleoli (Phase) and lack of increase in
DNA content (DAPI) with a single centrosome (Phase/anti-Tubulin)
indicate that the cell is in interphase. CTGF is shown to be accu-
mulated around the radial center of microtubule ¢bers (anti-CTGF/
anti-Tubulin), where the centrosome is located.
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already con¢rmed the intracellular accumulation of CTGF in
hypertrophic chondrocytes in cartilage (data not shown). Fur-
ther investigation is currently in progress.
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